{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T18:19:43Z","timestamp":1755800383128,"version":"3.41.2"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Recently, the safety of a new botulinum toxin (HU-014) was confirmed through animal experiments. The evaluation of the efficacy and safety of this newly introduced botulinum toxin is required considering the risk of adverse events (AEs) and need for standardization before its universal use.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>The aim of this multicenter, double-blind, randomized, parallel, active-controlled phase III clinical trial was to investigate the noninferiority of HU-014 versus existing onabotulinumtoxin A for the treatment of moderate to severe glabellar lines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>In total, 267 subjects were randomized to either the test (HU-014) or control (onabotulinumtoxin A) group. At the baseline and at weeks 4, 8, 12, and 16, investigator's live assessment, independent photographic assessment, subjects' improvement assessment, subjects' satisfaction assessment, and safety assessment were performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>At week 4, the response rate was 90.15% and 92.31% in the test and control groups, respectively, as per investigator's live assessment while frowning, without a significant difference. Both groups also showed no significant differences in response rates in the other assessments. In addition, no serious AEs were reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>HU-014 was noninferior to existing onabotulinumtoxin A in the treatment of glabellar lines at a 1:1 dose ratio, and both products were well tolerated.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000002789","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T16:38:33Z","timestamp":1611247113000},"page":"e91-e96","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and Safety of a New Botulinum Toxin (HU-014) Versus Existing Onabotulinumtoxin A in Subjects With Moderate to Severe Glabellar Lines"],"prefix":"10.1097","volume":"47","author":[{"given":"Kwang Ho","family":"Yoo","sequence":"first","affiliation":[{"name":"Department of Dermatology, College of Medicine, Chung-Ang University Hospital, Seoul, Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Dermatology, College of Medicine, Konkuk University Hospital, Seoul, Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Su","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Dermatology, College of Medicine, Konkuk University Hospital, Seoul, Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon Hyo","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Dermatology, College of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Hun","family":"Huh","sequence":"additional","affiliation":[{"name":"Department of Dermatology, College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beom Joon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, College of Medicine, Chung-Ang University Hospital, Seoul, Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,12,29]]},"reference":[{"key":"R1-20250731","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/DSS.0000000000001883","article-title":"OnabotulinumtoxinA for simultaneous treatment of upper facial lines: subject-reported satisfaction and impact from a phase 3 study","volume":"46","author":"Rivkin","year":"2020","journal-title":"Dermatol Surg"},{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/asj\/sjz172","article-title":"Multicenter efficacy trial of a percutaneous radiofrequency system for the reduction of glabellar lines","volume":"40","author":"Newman","year":"2020","journal-title":"Aesthet Surg J"},{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3390\/toxins9120403","article-title":"Botulinum toxin in the field of dermatology: novel indications","volume":"9","author":"Kim","year":"2017","journal-title":"Toxins (Basel)"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/dsu.12463","article-title":"Safety of botulinum toxin A in aesthetic treatments: a systematic review of clinical studies","volume":"40","author":"Cavallini","year":"2014","journal-title":"Dermatol Surg"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2147\/CCID.S227493","article-title":"Real-world safety and effectiveness of onabotulinumtoxin A treatment of crow's feet lines and glabellar lines: results of a Korean postmarketing surveillance study","volume":"19","author":"Yi","year":"2019","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R6-20250731","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1074\/jbc.M209821200","article-title":"Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons","volume":"278","author":"Foran","year":"2003","journal-title":"J Biol Chem"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"310e","DOI":"10.1097\/PRS.0000000000001544","article-title":"Efficacy and safety of botulinum toxin type A in the treatment of glabellar lines: a meta-analysis of randomized, placebo-controlled, double-blind trials","volume":"136","author":"Guo","year":"2015","journal-title":"Plast Reconstr Surg"},{"key":"R8-20250731","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/dsu.12100","article-title":"Multicenter, randomized, phase III study of a single dose of incobotulinumtoxin A, free from complexing proteins, in the treatment of glabellar frown lines","volume":"39","author":"Carruthers","year":"2013","journal-title":"Dermatol Surg"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"168","DOI":"10.7181\/acfs.2018.01886","article-title":"Safety, efficacy, and onset of a novel botulinum toxin type A (Nabota) for the treatment of glabellar frown lines: a single-arm, prospective, phase 4 clinical study","volume":"19","author":"Song","year":"2018","journal-title":"Arch Craniofac Surg"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s00266-008-9199-6","article-title":"A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects","volume":"32","author":"Harii","year":"2008","journal-title":"Aesthet Plast Surg"},{"key":"R11-20250731","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-4632.2009.04071.x","article-title":"An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects","volume":"48","author":"Kawashima","year":"2009","journal-title":"Int J Dermatol"},{"key":"R12-20250731","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/dsu.12072","article-title":"Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study","volume":"39","author":"Won","year":"2013","journal-title":"Dermatol Surg"},{"key":"R13-20250731","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1111\/jdv.12408","article-title":"Double-blind, randomized non-inferiority trial of a novel botulinum toxin A processed from the strain CBFC26, compared with onabotulinumtoxin A in the treatment of glabellar lines","volume":"28","author":"Kim","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R14-20250731","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/ijd.12627","article-title":"Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study","volume":"54","author":"Won","year":"2015","journal-title":"Int J Dermatol"},{"key":"R15-20250731","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1111\/j.1524-4725.2010.01739.x","article-title":"Development and validation of a 6-point grading scale in patients undergoing correction of nasolabial folds with a collagen implant","volume":"36","author":"Monheit","year":"2010","journal-title":"Dermatol Surg"},{"key":"R16-20250731","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/01.prs.0000279377.86280.8d","article-title":"Patient-reported benefit and satisfaction with botulinum toxin type A treatment of moderate to severe glabellar rhytides: results from a prospective open- label study","volume":"120","author":"Stotland","year":"2007","journal-title":"Plast Reconstr Surg"},{"key":"R17-20250731","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/DSS.0000000000000275","article-title":"Patient satisfaction and safety with aesthetic onabotulinumtoxinA after at least 5 years: a retrospective cross-sectional analysis of 4,402 glabellar treatments","volume":"41","author":"Trindade de Almeida","year":"2015","journal-title":"Dermatol Surg"},{"key":"R18-20250731","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/DSS.0000000000001779","article-title":"OnabotulinumtoxinA for treatment of forehead and glabellar lines: subject-reported satisfaction and impact from a phase 3 double-blind study","volume":"45","author":"Ogilvie","year":"2019","journal-title":"Dermatol Surg"},{"key":"R19-20250731","doi-asserted-by":"crossref","first-page":"847e","DOI":"10.1097\/PRS.0000000000005029","article-title":"Safety and efficacy of EB-001, a novel type E botulinum toxin, in subjects with glabellar frown lines: results of a phase 2, randomized, placebo-controlled, ascending-dose study","volume":"142","author":"Yoelin","year":"2018","journal-title":"Plast Reconstr Surg"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002789","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:11:36Z","timestamp":1753999896000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,29]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000002789","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"type":"print","value":"1076-0512"},{"type":"electronic","value":"1524-4725"}],"subject":[],"published":{"date-parts":[[2020,12,29]]}}}